Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI114252-01
Agency Tracking Number: R41AI114252
Amount: $586,535.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-124
Timeline
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-07-01
Award End Date (Contract End Date): 2016-06-30
Small Business Information
6042 CORNERSTONE CT, STE B, San Diego, CA, 92121-4746
DUNS: 832545805
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 GUNNAR KAUFMANN
 (858) 784-2517
 kaufmann@scripps.edu
Business Contact
 HENRY JI
Phone: (858) 210-3701
Email: hji@sorrentotherapeutics.com
Research Institution
 OHIO STATE UNIVERSITY
 1960 Kenny Road
Columbus, OH, 43210-1016
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Antibody therapy for serious bacterial infections using polyclonal immune antitoxin or anti capsule horse serum actually predates small molecule antibiotic use However for reasons of safety convenient empirical use and cost the development of broader spectrum antibiotics rapidly supplanted the use of immune serum But drug resistance is quickly reducing the number of effective antibiotics available for treatment of severe bacterial infections while advances in human monoclonal antibody mAb technologies have led to reconsideration of immunotherapies Therefore passive immunotherapies could be effective in preventing or treating high risk infections caused by drug resistant bacterial pathogens such as Pseudomonas aeruginosa a highly adaptable opportunistic bacterium Our target antigens for this proposal the outer membrane proteins OprF and OprI were chosen because of sequence conservation among clinical isolates and their use as vaccine antigens in several clinical trials Sorrento Therapeutics Inc has developed proprietary technologies namely its G MAB R library for selection of fully human antibodies as well as andquot antibody formulated drug conjugateandquot AfDC methodology for generation of targeted micelles We propose to generate and evaluate anti OpfF I mAbs as well as AfDCs i e colistin sulfate azithromycin containing micelles linked to selected anti P aeruginosa mAbs The studies will be performed together with our academic collaborator Dr Daniel Wozniak Ohio State University The most promising mAbs and AfDCs will be thoroughly evaluated in vitro and in vivo for their ability to prevent and or treat local as well as systemic P aeruginosa infection Specifically the projects of our STTR Advanced Technology Phase I grant application are Project In vitro evaluation and prioritization of the selected human anti OprF I mAbs Project Generation and in vitro evaluation of anti Pseudomonas AfDCs Project In vivo evaluation of mAbs AfDCs in murine and porcine P aeruginosa infection models The proposed product a fully human anti P aeruginosa mAb immunotherapy or an AfDC as targeted antibiotic delivery vehicle would be an effective and safe stand alone and or member of a andquot cocktailandquot therapeutic option for prevention or treatment of P aeruginosa infections PUBLIC HEALTH RELEVANCE Advances in human monoclonal antibody mAb technologies might enable development of passive immunotherapies for prevention or treatment of high risk infections caused by drug resistant bacteria such as Pseudomonas aeruginosa Our proposed product will be a fully human anti P aeruginosa mAb immunotherapy or an antibody mediated targeted antibiotic delivery vehicle as effective and safe stand alone and or member of a andquot cocktailandquot therapeutic option for prevention or treatment of P aeruginosa infections

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government